Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

This first-in-human study (NCT03032588), conducted in Belgium, evaluated a new inactivated poliovirus vaccines (IPV) candidate based on Sabin poliovirus strains grown on the high-yield PER.C6® cell line. Healthy adults (N = 32) were randomized (1:1) to receive a single dose of PER.C6-based Sabin-IPV...

Descripción completa

Detalles Bibliográficos
Autores principales: Leroux-Roels, Isabel, Leroux-Roels, Geert, Shukarev, Georgi, Schuitemaker, Hanneke, Cahill, Conor, de Rooij, Richard, Struijs, Martin, van Zeeburg, Hester, Jacquet, Jeanne-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078678/
https://www.ncbi.nlm.nih.gov/pubmed/33175637
http://dx.doi.org/10.1080/21645515.2020.1812315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078678/
https://www.ncbi.nlm.nih.gov/pubmed/33175637
http://dx.doi.org/10.1080/21645515.2020.1812315

Ejemplares similares